Across TCGA pan-cancer cohorts, APRT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APRT data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher APRT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated APRT expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, PDAC, and COAD are the cancer types where APRT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.745	0.346	.002	14	view →
PDAC	OS	Median	IV	0.381	0.951	.006	13	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	2	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: APRT tumor-vs-normal RNA expression · all APRT data types